ENGLEWOOD, Colo., Nov. 15, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Company has been ranked within Forbes' list of America's Most Successful Small-Cap Companies for 2024. The 2024 Forbes list of America's Most Successful Small-Cap Companies can be found at www.forbes.com.
"We are honored to be included in Forbes' Most Successful Small-Cap Companies list for the fourth year in a row," said Thomas Sandgaard, CEO of Zynex. "We believe our emphasis on providing non-invasive patient solutions leads to consistent revenue and profitability growth that will allow Zynex to become the world's premier pain management provider."
The data used to analyze the companies on the list was compiled from FactSet. Forbes screened over 1,000 small cap companies and narrowed the list down to 389 of which had positive sales growth over the past twelve months and a share price of at least $5. The rankings are based on many factors, including earnings growth, sales growth, return on equity, and total stock return for the trailing twelve months and over the last five years.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$8.18 |
Daily Change: | -0.04 -0.49 |
Daily Volume: | 14,280 |
Market Cap: | US$260.530M |
October 24, 2024 September 04, 2024 September 03, 2024 July 25, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB